" /> Regdanvimab - CISMeF





Preferred Label : Regdanvimab;

NCIt definition : A neutralizing, human immunoglobulin G1 (IgG1) monoclonal antibody directed against the spike (S) protein receptor binding domain (RBD) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against Coronavirus disease 2019 (COVID-19). Upon administration, regdanvimab specifically targets and binds to the RBD of the SARS-CoV-2 S protein. This blocks viral attachment and entry into human host cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may also provide temporary protection against infection with SARS-CoV-2. S-protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.;

UNII : I0BGE6P6I6;

CAS number : 2444308-95-4; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2444308-95-4 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : CTP 59; CTP-59;

NCI Metathesaurus CUI : CL1642822;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
22/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.